Bellerophon Therapeutics LLC, a clinical stage biotherapeutics company based in Hampton, announced Wednesday that Jonathan Peacock has been appointed chairman and CEO.
Peacock took over the role from Daniel Tasse, chairman and CEO of Ikaria Inc., who has been the interim chairman and CEO of Bellerophon since the company’s spin-out from Ikaria in February.
"We are delighted to welcome Jon to Bellerophon as chairman and chief executive officer," Tasse said in a prepared statement. "He brings great leadership skills, broad industry experience and deep expertise in a range of areas including business development, strategy and capital markets. This key appointment will help to both move the company's innovative therapeutic pipeline forward and achieve its broader strategic ambitions."
Previously, Peacock was the executive vice president and chief financial officer of Amgen. Prior to that, he was the chief financial and administrative officer of Novartis Pharmaceuticals AG. He was also partner at McKinsey and Co. and Price Waterhouse.
"We look forward to working with Jon as we continue to provide strong support to Bellerophon, as it focuses on developing therapeutics at the intersection of drugs and devices,” Matt Holt, managing director of New Mountain Capital and board member of Bellerophon, said in a prepared statement. “Jon's experience and talents align well to the opportunity at hand."
Commenting on his appointment, Peacock said: "I am excited to join Bellerophon. I believe the company has great potential, first in the development of three innovative first-in-class programs potentially entering Phase 3 development in the next 12 to 18 months, and also in the opportunity to build a broader business around this strong platform of assets and capabilities. In addition, the company's focus on developing new treatments to address important unmet medical needs within the cardiopulmonary and cardiac disease space provides a clear mission to help patients."
ALSO ON NJBIZ: